Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 37, Issue 1, 2012, Pages 62-75

  Hwang, Rudi ^a   Tiwari, Arun K ^a   Zai, Clement C ^a   Felsky, Daniel ^a   Remington, Eli ^a   Wallace, Tessa ^a   Tong, Ryan P ^a   Souza, Renan P ^b   Oh, Gabriel ^a   Potkin, Steven G ^c   Lieberman, Jeffrey A ^d   Meltzer, Herbert Y ^e   Kennedy, James L ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Antipsychotic; Clozapine; Dopamine D4 receptor gene (DRD4); Dopamine D5 receptor gene (DRD5); Pharmacogenetics; Response

Indexed keywords

CLOZAPINE; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR;

ALLELE; ARTICLE; CONTROLLED STUDY; DRD4 GENE; DRD5 GENE; DRUG BLOOD LEVEL; DRUG RESPONSE; EXON; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; PATIENT COMPLIANCE; PHENOTYPE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIPSYCHOTIC AGENTS; CLOZAPINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECEPTORS, DOPAMINE D4; RECEPTORS, DOPAMINE D5; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84857794653     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.11.018     Document Type: Article

References (100)

1. Adamson M.D., Kennedy J., Petronis A., Dean M., Virkkunen M., Linnoila M., Goldman D. DRD4 dopamine receptor genotype and CSF monoamine metabolites in Finnish alcoholics and controls. Am J Med Genet 1995, 60:199-205.
2. Andreasen N.C. Linking mind and brain in the study of mental illnesses: a project for a scientific psychopathology. Science 1997, 275:1586-1593.
3. APA Diagnostic and statistical manual of mental disorders (DSM-IV) 1994, American Psychiatric Association, Washington, DC. 4th edn.
4. Asghari V., Sanyal S., Buchwaldt S., Paterson A., Jovanovic V., Van Tol H.H. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 1995, 65:1157-1165.
5. Asghari V., Schoots O., van Kats S., Ohara K., Jovanovic V., Guan H.C., Bunzow J.R., Petronis A., Van Tol H.H. Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol Pharmacol 1994, 46:364-373.
6. Basile V.S., Masellis M., Potkin S.G., Kennedy J.L. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002, 11:2517-2530.
7. Bergson C., Mrzljak L., Smiley J.F., Pappy M., Levenson R., Goldman-Rakic P.S. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J Neurosci 1995, 15:7821-7836.
8. Buchner A., Erdfelder E., Faul F. How to use G*Power [WWW document]. URL. http://www.psycho.uni-duesseldorf.de/aap/projects/gpower/how_to_use_gpower.html.
9. Congdon E., Lesch K.P., Canli T. Analysis of DRD4 and DAT polymorphisms and behavioral inhibition in healthy adults: implications for impulsivity. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:27-32.
10. D'Souza U.M., Russ C., Tahir E., Mill J., McGuffin P., Asherson P.J., Craig I.W. Functional effects of a tandem duplication polymorphism in the 5'flanking region of the DRD4 gene. Biol Psychiatry 2004, 56:691-697.
11. Davidson M., Harvey P.D., Bergman R.L., Powchik P., Kaminsky R., Losonczy M.F., Davis K.L. Effects of the D-1 agonist SKF-38393 combined with haloperidol in schizophrenic patients. Arch Gen Psychiatry 1990, 47:190-191.
12. de Almeida J., Palacios J.M., Mengod G. Distribution of 5-HT and DA receptors in primate prefrontal cortex: implications for pathophysiology and treatment. Prog Brain Res 2008, 172:101-115.
13. Den Boer J.A., van Megen H.J., Fleischhacker W.W., Louwerens J.W., Slaap B.R., Westenberg H.G., Burrows G.D., Srivastava O.N. Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology (Berl) 1995, 121:317-322.
14. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008, 2008(66):87-98.
15. Gaunt T.R., Rodriguez S., Zapata C., Day I.N. MIDAS: software for analysis and visualisation of interallelic disequilibrium between multiallelic markers. BMC Bioinformatics 2006, 7:227.
16. Goldberg T.E., David A., Gold J.M. Neurocognitive deficits in schizophrenia. Schizophrenia 1995, Blackwell, Oxford. S.R. Hirsch, D.R. Weinberger (Eds.).
17. Golimbet V.E., Alfimova M.V., Gritsenko I.K., Lezheiko T.V., Ebstein R. Association of dopamine receptor D5 gene polymorphism with peculiarities of voluntary attention in schizophrenic patients and their relatives. Bull Exp Biol Med 2008, 145:65-67.
18. Grafman J., Vance S.C., Weingartner H., Salazar A.M., Amin D. The effects of lateralized frontal lesions on mood regulation. Brain 1986, 109(Pt 6):1127-1148.
19. Hamarman S., Fossella J., Ulger C., Brimacombe M., Dermody J. Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. J Child Adolesc Psychopharmacol 2004, 14:564-574.
20. Hedrick P.W. Gametic disequilibrium measures: proceed with caution. Genetics 1987, 117:331-341.
21. Herrmann M.J., Walter A., Schreppel T., Ehlis A.C., Pauli P., Lesch K.P., Fallgatter A.J. D4 receptor gene variation modulates activation of prefrontal cortex during working memory. Eur J Neurosci 2007, 26:2713-2718.
22. Hersi A.I., Kitaichi K., Srivastava L.K., Gaudreau P., Quirion R. Dopamine D-5 receptor modulates hippocampal acetylcholine release. Brain Res Mol Brain Res 2000, 76:336-340.
23. Hoyer C., Kranaster L., Leweke F.M., Klosterkotter J., Meyer-Lindenberg A., Koethe D. Familial differential treatment response in schizophrenia-lessons from a case of three affected siblings. Pharmacopsychiatry 2010, 43:196-197.
24. Hutchison K.E., Stallings M., McGeary J., Bryan A. Population stratification in the candidate gene study: fatal threat or red herring?. Psychol Bull 2004, 30:66-79.
25. Hwang R., Shinkai T., De Luca V., Muller D.J., Ni X., Macciardi F., Potkin S., Lieberman J.A., Meltzer H.Y., Kennedy J.L. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl) 2005, 181:179-187.
26. Hwang R., Shinkai T., De Luca V., Ni X., Potkin S.G., Lieberman J.A., Meltzer H.Y., Kennedy J.L. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol 2007, 21:718-727.
27. Hwang R., Shinkai T., Deluca V., Macciardi F., Potkin S., Meltzer H.Y., Kennedy J.L. Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. Eur Neuropsychopharmacol 2006, 16:248-259.
28. Hwang R., Zai C., Tiwari A., Muller D.J., Arranz M.J., Morris A.G., McKenna P.J., Munro J., Potkin S.G., Lieberman J.A., Meltzer H.Y., Kennedy J.L. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J 2010, 10:200-218.
29. Hwu H.G., Hong C.J., Lee Y.L., Lee P.C., Lee S.F. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol Psychiatry 1998, 44:483-487.
30. IHMC The international HapMap project. Nature 2003, 426:789-796.
31. Ikeda M., Yamanouchi Y., Kinoshita Y., Kitajima T., Yoshimura R., Hashimoto S., O'Donovan M.C., Nakamura J., Ozaki N., Iwata N. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008, 9:1437-1443.
32. Johnson A.D., Zhang Y., Papp A.C., Pinsonneault J.K., Lim J.E., Saffen D., Dai Z., Wang D., Sadee W. Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet Genomics 2008, 18:781-791.
33. Jovanovic V., Guan H.C., Van Tol H.H. Comparative pharmacological and functional analysis of the human dopamine D4.2 and D4.10 receptor variants. Pharmacogenetics 1999, 9:561-568.
34. Kaiser R., Konneker M., Henneken M., Dettling M., Muller-Oerlinghausen B., Roots I., Brockmoller J. Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry 2000, 5:418-424.
35. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45:789-796.
36. Kane J.M. The current status of neuroleptic therapy. J Clin Psychiatry 1989, 50:322-328.
37. Kapur S., Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1081-1090.
38. Karle J., Clemmesen L., Hansen L., Andersen M., Andersen J., Fensbo C., Sloth-Nielsen M., Skrumsager B.K., Lublin H., Gerlach J. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology (Berl) 1995, 121:328-329.
39. Kazmi M.A., Snyder L.A., Cypess A.M., Graber S.G., Sakmar T.P. Selective reconstitution of human D4 dopamine receptor variants with Gi alpha subtypes. Biochemistry 2000, 39:3734-3744.
40. Kereszturi E., Kiraly O., Csapo Z., Tarnok Z., Gadoros J., Sasvari-Szekely M., Nemoda Z. Association between the 120-bp duplication of the dopamine D4 receptor gene and attention deficit hyperactivity disorder: genetic and molecular analyses. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:231-236.
41. Kohn Y., Ebstein R.P., Heresco-Levy U., Shapira B., Nemanov L., Gritsenko I., Avnon M., Lerer B. Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur Neuropsychopharmacol 1997, 7:39-43.
42. Lahiri D.K., Nurnberger J.I. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991, 19:5444.
43. Lewontin R.C. The interaction of selection and linkage. I. General considerations; heterotic models. Genetics 1964, 49:49-67.
44. Li D., Sham P.C., Owen M.J., He L. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet 2006, 15:2276-2284.
45. Lichter J.B., Barr C.L., Kennedy J.L., Van Tol H.H., Kidd K.K., Livak K.J. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 1993, 2:767-773.
46. Lidow M.S., Elsworth J.D., Goldman-Rakic P.S. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. The Journal of pharmacology and experimental therapeutics. J Pharmacol Exp Ther 1997, 281:597-603.
47. Lidow M.S., Goldman-Rakic P.S. A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci U S A 1994, 91:4353-4356.
48. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
49. Maher B.S., Marazita M.L., Ferrell R.E., Vanyukov M.M. Dopamine system genes and attention deficit hyperactivity disorder: a meta-analysis. Psychiatr Genet 2002, 12:207-215.
50. Mata I., Madoz V., Arranz M.J., Sham P., Murray R.M. Olanzapine: concordant response in monozygotic twins with schizophrenia. Br J Psychiatry 2001, 178:86.
51. McGeary J. The DRD4 exon 3 VNTR polymorphism and addiction-related phenotypes: a review. Pharmacol Biochem Behav 2009, 93:222-229.
52. McGough J., McCracken J., Swanson J., Riddle M., Kollins S., Greenhill L., Abikoff H., Davies M., Chuang S., Wigal T., Wigal S., Posner K., Skrobala A., Kastelic E., Ghuman J., Cunningham C., Shigawa S., Moyzis R., Vitiello B. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006, 45:1314-1322.
53. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991, 17:263-287.
54. Mill J., Xu X., Ronald A., Curran S., Price T., Knight J., Craig I., Sham P., Plomin R., Asherson P. Quantitative trait locus analysis of candidate gene alleles associated with attention deficit hyperactivity disorder (ADHD) in five genes: DRD4, DAT1, DRD5, SNAP-25, and 5HT1B. Am J Med Genet B Neuropsychiatr Genet 2005, 133B:68-73.
55. Muir W.J., Thomson M.L., McKeon P., Mynett-Johnson L., Whitton C., Evans K.L., Porteous D.J., Blackwood D.H. Markers close to the dopamine D5 receptor gene (DRD5) show significant association with schizophrenia but not bipolar disorder. Am J Med Genet 2001, 105:152-158.
56. Muto A., Hoshino H., Madisen L., Yanai N., Obinata M., Karasuyama H., Hayashi N., Nakauchi H., Yamamoto M., Groudine M., Igarashi K. Identification of Bach2 as a B-cell-specific partner for small maf proteins that negatively regulate the immunoglobulin heavy chain gene 3' enhancer. EMBO J 1998, 17:5734-5743.
57. Nyholt D.R. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004, 74:765-769.
58. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., Someya Y., Sassa T., Sudo Y., Matsushima E., Iyo M., Tateno Y., Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997, 385:634-636.
59. Ott J. Analysis of human genetic linkage. 3rd 1999, Johns Hopkins University Press, Baltimore. edition ed.
60. Ozdemir V., Masellis M., Basile V.S., Kalow W., Meltzer H.Y., Lieberman J.A., Kennedy J.L. Variability in response to clozapine: potential role of cytochrome P450 1A2 and the dopamine D4 receptor gene. CNS Spectr 1999, 4:30-56.
61. Pankow J.S., Province M.A., Hunt S.C., Arnett D.K. Regarding "Testing for population subdivision and association in four case-control studies". Am J Hum Genet 2002, 71:1478-1480.
62. Petronis A., O'Hara K., Barr C.L., Kennedy J.L., Van Tol H.H. (G)n-mononucleotide polymorphism in the human D4 dopamine receptor (DRD4) gene. Hum Genet 1994, 93:719.
63. Pinte S., Stankovic-Valentin N., Deltour S., Rood B.R., Guerardel C., Leprince D. The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties. J Biol Chem 2004, 279:38313-38324.
64. Potkin S.G., Basile V.S., Jin Y., Masellis M., Badri F., Keator D., Wu J.C., Alva G., Carreon D.T., Bunney W.E., Fallon J.H., Kennedy J.L. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 2003, 8:109-113.
65. Rao P.A., Pickar D., Gejman P.V., Ram A., Gershon E.S., Gelernter J. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry 1994, 51:912-917.
66. Reist C., Ozdemir V., Wang E., Hashemzadeh M., Mee S., Moyzis R. Novelty seeking and the dopamine D4 receptor gene (DRD4) revisited in Asians: haplotype characterization and relevance of the 2-repeat allele. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:453-457.
67. Rice T.K., Schork N.J., Rao D.C. Methods for handling multiple testing. Adv Genet 2008, 60:293-308.
68. Rietschel M., Naber D., Oberländer H., Holzbach R., Fimmers R., Eggermann K., Möller H.J., Propping P., Nöthen M.M. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 1996, 15:491-496.
69. Ronai Z., Guttman A., Keszler G., Sasvari-Szekely M. Capillary electrophoresis study on DNA-protein complex formation in the polymorphic 5' upstream region of the dopamine D4 receptor (DRD4) gene. Curr Med Chem 2004, 11:1023-1029.
70. Sanak M., Zelek-Molik A., Nalepa I., Wegrzyn J., Wciorka J. The dopamine D4 receptor VNTR in Polish schizophrenia patients. Schizophr Res 2005, 73:129-131.
71. Schoots O., Van Tol H.H. The human dopamine D4 receptor repeat sequences modulate expression. Pharmacogenomics J 2003, 3:343-348.
72. Seaman M.I., Fisher J.B., Chang F., Kidd K.K. Tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4). Am J Med Genet 1999, 88:705-709.
73. Sedvall G., Farde L. Dopamine receptors in schizophrenia. Lancet 1996, 347:264.
74. Seeman P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 2010, 4:56-73.
75. Seeman P., Guan H.C., Van Tol H.H. Dopamine D4 receptors elevated in schizophrenia. Nature 1993, 365:441-445.
76. Shaikh S., Collier D., Kerwin R.W., Pilowsky L.S., Gill M., Xu W.M., Thornton A. Dopamine D4 receptor subtypes and response to clozapine. Lancet 1993, 341:116.
77. Shaikh S., Collier D.A., Sham P., Pilowsky L., Sharma T., Lin L.K., Crocq M.A., Gill M., Kerwin R. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Genet 1995, 60:541-545.
78. Shaikh S., Kerwin R., Sham P., Sharma T., Collier D. D4 polymorphisms in schizophrenic patients treated with clozapine. Schizophr Res 1994, 15:165-166.
79. Sherrington R., Mankoo B., Attwood J., Kalsi G., Curtis D., Buetow K., Povey S., Gurling H. Cloning of the human dopamine D5 receptor gene and identification of a highly polymorphic microsatellite for the DRD5 locus that shows tight linkage to the chromosome 4p reference marker RAF1P1. Genomics 1993, 18:423-425.
80. Simpson J., Vetuz G., Wilson M., Brookes K.J., Kent L. The DRD4 receptor Exon 3 VNTR and 5' SNP variants and mRNA expression in human post-mortem brain tissue. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:1228-1233.
81. So C.H., Verma V., Alijaniaram M., Cheng R., Rashid A.J., O'Dowd B.F., George S.R. Calcium signaling by dopamine D5 receptor and D5-D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1-D2 receptor hetero-oligomers. Mol Pharmacol 2009, 75:843-854.
82. SPSS Statistical package for the social sciences for Windows, rel. 17.0.0 2008, SPSS Inc, Chicago.
83. Stefanis N.C., Bresnick J.N., Kerwin R.W., Schofield W.N., McAllister G. Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain. Brain Res Mol Brain Res 1998, 53:112-119.
84. Sunahara R.K., Guan H.C., O'Dowd B.F., Seeman P., Laurier L.G., Ng G., George S.R., Torchia J., Van Tol H.H., Niznik H.B. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991, 350:614-619.
85. Szekely A., Balota D.A., Duchek J.M., Nemoda Z., Vereczkei A., Sasvari-Szekely M. Genetic factors of reaction time performance: DRD4 7-repeat allele associated with slower responses. Genes Brain Behav 2011, 10:129-136.
86. Thomas P., Srivastava V., Singh A., Mathur P., Nimgaonkar V.L., Lerer B., Thelma B.K., Deshpande S.N. Correlates of response to olanzapine in a North Indian Schizophrenia sample. Psychiatry Res 2008, 161:275-283.
87. Van Craenenbroeck K., Clark S.D., Cox M.J., Oak J.N., Liu F., Van Tol H.H. Folding efficiency is rate-limiting in dopamine D4 receptor biogenesis. J Biol Chem 2005, 280:19350-19357.
88. Van Tol H.H., Bunzow J.R., Guan H.C., Sunahara R.K., Seeman P., Niznik H.B., Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991, 350:610-614.
89. Van Tol H.H., Wu C.M., Guan H.C., Ohara K., Bunzow J.R., Civelli O., Kennedy J., Seeman P., Niznik H.B., Jovanovic V. Multiple dopamine D4 receptor variants in the human population. Nature 1992, 358:149-152.
90. Vojvoda D., Grimmell K., Sernyak M., Mazure C.M. Monozygotic twins concordant for response to clozapine. Lancet 1996, 347:61.
91. Wang E., Ding Y.C., Flodman P., Kidd J.R., Kidd K.K., Grady D.L., Ryder O.A., Spence M.A., Swanson J.M., Moyzis R.K. The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus. Am J Hum Genet 2004, 74:931-944.
92. Weinberger D. Dopamine, the prefrontal cortex, and a genetic mechanism of schizophrenia. Dopamine in the pathophysiology and treatment of schizophrenia 2003, Martin Dunitz, London and New York. Y. Lecrubier, S. Kapur (Eds.).
93. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995, 376:572-575.
94. Williams N.M., Cardno A.G., Murphy K.C., Jones L.A., Asherson P., McGuffin P., Owen M.J. Association between schizophrenia and a microsatellite polymorphism at the dopamine D5 receptor gene. Psychiatr Genet 1997, 7:83-85.
95. Woods A.S. The dopamine D(4) receptor, the ultimate disordered protein. J Recept Signal Transduct Res 2010, 30:331-336.
96. Zalsman G., Frisch A., Lev-Ran S., Martin A., Michaelovsky E., Bensason D., Gothelf D., Nahshoni E., Tyano S., Weizman A. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. Eur Neuropsychopharmacol 2003, 13:183-185.
97. Zapata C., Rodriguez S., Visedo G., Sacristan F. Spectrum of nonrandom associations between microsatellite loci on human chromosome 11p15. Genetics 2001, 158:1235-1251.
98. Zhang J.P., Lencz T., Malhotra A.K. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010, 167:763-772.
99. Zhang J.P., Malhotra A.K. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011, 7:9-37.
100. Zhao A.L., Zhao J.P., Zhang Y.H., Xue Z.M., Chen J.D., Chen X.G. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci 2005, 115:1539-1547.